📣 Yesterday, August 14 2023, the The Lancet published a ground-breaking three-paper series on pulmonary hypertension.
1️⃣ In the first paper, Prof. Marc Humbert and colleagues provide an overview of the pathophysiology of pulmonary arterial hypertension, current therapeutic approaches, and emerging treatment options, with a forward-looking discussion of innovative solutions for future clinical trials. We are delighted that pulmonary hypertension patient and longtime patient advocate Melanie Gallant-Dewavrin, director of HTaPFrance, the French pulmonary hypertension patient association, is one of the co-authors! This is not only an important personal achievement for Mélanie, but also holds special meaning for patients and their advocates as a whole. It stands as a strong testament to the strength and unity of the patient community, resonating with the uplifting notes of progress and empowerment.
2️⃣ In the second paper Karen M. Olsson and colleagues consider the patho-mechanisms of pulmonary hypertension associated with lung disease, outline approaches to diagnosis and management, and emphasise the need for safe, effective treatment options and non-invasive diagnostic tools to detect and characterise pulmonary hypertension in this patient population.
3️⃣ In the third paper, Marion Delcroix and colleagues review the anatomy and pathophysiology of chronic thromboembolic pulmonary hypertension, describe surgical, interventional, and medical therapeutic options, and outline approaches to multimodal management.
Read more at this link on the Lancet website